The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update
Open accessAbstract
PURPOSE: To update the ASCO guideline on pharmacologic interventions for breast cancer risk reduction and provide guidance on clinical issues that arise when deciding to use endocrine therapy for breast cancer risk reduction. METHODS: An Expert Panel conducted targeted systematic literature reviews to identify new studies. RESULTS: A randomized clinical trial that evaluated the use of anastrozole for reduction of estrogen receptor–positive breast cancers in postmenopausal women at increased risk of developing breast cancer provided the predominant basis for the update. UPDATED RECOMMENDATIONS: In postmenopausal women at increased risk, the choice of endocrine therapy now includes anastrozole (1 mg/day) in addition to exemestane (25 mg/day), raloxifene (60 mg/day), or tamoxifen (20 mg/day). The decision regarding choice of endocrine therapy should take into consideration age, baseline comorbidities, and adverse effect profiles. Clinicians should not prescribe anastrozole, exemestane, or raloxifene for breast cancer risk reduction to premenopausal women. Tamoxifen 20 mg/day for 5 years is still considered standard of care for risk reduction in premenopausal women who are at least 35 years old and have completed childbearing. Data on low-dose tamoxifen as an alternative to the standard dose for both pre- and postmenopausal women with intraepithelial neoplasia are discussed in the Clinical Considerations section of this article. Additional information is available at www.asco.org/breast-cancer-guidelines .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A breast cancer prediction model incorporating familial and personal risk factors
Tyrer, J., Duffy, S. W., & Cuzick, J. (2004) · Statistics in Medicine · doi:10.1002/sim.1668 · Cited by 1,345
Exemestane for Breast-Cancer Prevention in Postmenopausal Women
Goss, P. E., Ingle, J. N., Alés-Martínez, J. E., Cheung, A. M., Chlebowski, R. T., Wactawski-Wende, J., McTiernan, A., Robbins, J., Johnson, K. C., Martin, L. W., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103507 · Cited by 970
Self-citationHow Quickly Do Systematic Reviews Go Out of Date? A Survival Analysis
Shojania, K. G., Sampson, M., Ansari, M. T., Ji, J., Doucette, S., & Moher, D. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-4-200708210-00179 · Cited by 838 · cited 1×
“ASCO uses a signals approach to facilitate guideline updating.(7) This approach identifies new, potentially practice-changing data (signals) that might translate into revised practice recommendations.”
MethodCuzick, J., Sestak, I., Forbes, J. F., Dowsett, M., Knox, J., Cawthorn, S., Saunders, C., Roche, N., Mansel, R. E., von Minckwitz, G., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62292-8 · Cited by 590
Maas, P., Barrdahl, M., Joshi, A. D., Auer, P. L., Gaudet, M. M., Milne, R. L., Schumacher, F. R., Anderson, W. F., Check, D., Chattopadhyay, S., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1025 · Cited by 373
Smith, S. G., Sestak, I., Howell, A., Forbes, J., & Cuzick, J. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.7439 · Cited by 51
Sestak, I., Smith, S. G., Howell, A., Forbes, J. F., & Cuzick, J. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx713 · Cited by 27
Cited by
Key steps for effective breast cancer prevention
Britt, K. L., Cuzick, J., & Phillips, K.-A. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0266-x · Cited by 992
Nielsen, T. O., Leung, S. C. Y., Rimm, D. L., Dodson, A., Acs, B., Badve, S., Denkert, C., Ellis, M. J., Fineberg, S., Flowers, M., et al. (2021) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djaa201 · Cited by 753
Chlebowski, R. T., Anderson, G. L., Aragaki, A. K., Manson, J. E., Stefanick, M. L., Pan, K., Barrington, W., Kuller, L. H., Simon, M. S., Lane, D., et al. (2020) · JAMA · doi:10.1001/jama.2020.9482 · Cited by 427
Ross, E. L., Zuromski, K. L., Reis, B. Y., Nock, M. K., Kessler, R. C., & Smoller, J. W. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.0089 · Cited by 65
Metadata
- Authors
- Visvanathan, K., Fabian, C. J., Bantug, E., Brewster, A. M., Davidson, N. E., DeCensi, A., Floyd, J. D., Garber, J. E., Hofstatter, E. W., Khan, S. A., Katapodi, M. C., Pruthi, S., Raab, R., Runowicz, C. D., & Somerfield, M. R.
- Venue
- Journal of Clinical Oncology
- Published
- 2019-11-20
- Volume
- 37
- Issue
- 33
- Pages
- 3152-3165
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2971583637
- Cited by
- 218
- References
- 7
- FWCI
- 10.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.